***Biographical Sketch***

**Elena E Solomou, MD, PhD**

**Professor Internal Medicine-Hematology**

**University of Patras Medical School**

**Rion 26504**

**Greece**

|  |
| --- |
| Personal Information |
| SURNAME  | Solomou |
| name  | ELENA |
| date of birth  | 25/9/1973 (CYPRUS) |
| place of Residence  | PATRAS, GREECE |
| e-mail  | esolomou@upatras.gr, elenasolomou@hotmail.com |
| tel.  | +30-6970839894 |

|  |
| --- |
|  |
| CURRENT POSITION(S) |
|  |
| 5.2024-today  | Professor in Internal Medicine - Hematology-University of Patras Medical School |
| 05.2020 – 5.2024 | Associate Professor in Internal Medicine - Hematology-University of Patras Medical School |
| 09.2021 – 9.2022 | Visiting Professor, National and Kapodistrian University of Athens Medical School  |

|  |
| --- |
| PREVIOUS POSITIONS |
| 05.2017 – 05.2020 | Assistant Professor in Internal Medicine-Hematology, University of Patras Medical School (tenured) |
| 1.2013 – 05.2017 | Assistant Professor in Internal Medicine-Hematology, University of Patras Medical School  |
| 01.2008 – 12.2012 | Lecturer in Internal Medicine, University of Patras Medical School  |
| 03.2005-11-2007 | Postdoctoral Fellow, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, (ΝΙΗ), Bethesda, Maryland, USA (Chief: Dr. Neal S. Young).  |
|  |  |
| EDUCATION |  |
| 7.2019 | Board Certified in Internal Medicine (Greece)  |  |
| 7.2007 | Board Certified Hematologist (Greece). |  |
| 2005-2006 | Translational Research in Clinical Oncology (TRACO Course, 2005-2006) National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Postgraduate course in clinical oncology for medical doctors interested in oncology (certificate) |  |
| 3.2005 - 9.2006 | Clinical Fellow in Hematology, Hematology Branch, National Heart Lung and Blood Institute, NIH, Bethesda, Maryland, USA |  |
| 09.2002 – 03.2005 | Clinical Fellow in Hematology , Patras University Hospital, Dept of Internal Medicine, Division of Hematology |  |
| 3.2001-9.2002 | Clinical Fellow, “Laikon” General Hospital of Athens. 1st Propedeutic Dept of Internal Medicine. Internal Medicine. |  |
| 09.2002 | PhD thesis. Title: «Identification and characterization of a novel gene in the chromosomal region 13q14. This gene acts as nucleotide exchange factor and is deleted in patients with Chronic Lymphocytic Leukemia».Department of Internal Medicine, University of Athens Medical School, Degree: “Excellent” |  |
| 2.2000-3.2001 | Dept of Internal Medicine, Walter Reed Army Hospital, of the Uniformed Services University of the Health Sciences (USUHS). Internal Medicine |  |
| 09.1998 – 6.2000 | Master’s Degree in Clinical and Experimental Medicine, University of Athens Medical School. Specialization in Hematology. Thesis: Identification of a novel gene in the chromosomal region 13q14 |  |
| 09.1997 | Graduation from the Medical School, National and Kapodistrian University of Athens Medical School  |  |

**Publications:**

1. Solomou EE, YT Juang, MF Gourley, GM Kammer, GC Tsokos. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus.

Journal of Immunology, 2001; 166: 4216-4222.

2. Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis M, Sfikakis PP. B-cell kinase Lyn deficiency in patients with systemic lupus erythematosus.

Journal of Investigative Medicine 2001; 49:157-165.

3. Solomou EE, YT Juang, GC Tsokos. PKC-θ participates in the activation of CREB and its subsequent binding on the -180 site of the IL-2 promoter in normal human T lymphocytes.

Journal of Immunology,2001; 166: 5665-5674.

4. Juang YT, EE Solomou, B Rellahan, MF Gourley, GC Tsokos. Phosphorylation and O-linked glycosylation of Elf-1 leads to its translocation to the nucleus and binding to the promoter of the TCR-zeta chain.

Journal of Immunology*,* 2002; 168:2865-2871.

5. Herndon TM, YT Juang, EE Solomou, SW Rothwell, MF Gourley, GC Tsokos. Electroporation mediated gene transfer of p65 into T lymphocytes from Systemic Lupus Erythematosus patients leads to increased levels of interleukin-2 promoter activity.

Clinical Immunology, 2002; 103: 145-53.

6. Solomou EE, Sfikakis PP, Kotsi P, Papaioannou M, Karali V, Vervessou E, Hoffbrand AV, Panayiotidis P. Identification of a new gene that maps on the 13q14.3 chromosomal region and acts as a guanine nucleotide factor.

Leukemia and Lymphoma, 2003; 44:1579-85.

7. Juang YT, Wang Y, EE Solomou, Li Y, Marwin C, Tenbrock K, Kyttaris V, Tsokos GC. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 productin through CaMKIV.

 Journal of Clinical Investigation, 2005; 115 (4):996-1005).

8. Monastirli A, Matsouka P, Pasmatzi E, Melachrinou M, Georgiou S, Solomou EE, Zoumbos N, Tsambaos D. Complete remission of recalcitrant viral warts under oral isotretinoin in a patient with low-grade B-cell lymphoma.

 Acta Dermato-Venereologica, 2005; 85(4): 358-360.

9. Solomou EE, Keyvanfar K and Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia.

Blood, 2006; 107: 3983-3991.

10. Symeonidis A, Kouraklis-Symeonidis A, Constandinidou I, Solomou EE, Kougelou S, Vassilakos P, Zoumbos N. Increased CA-15.3 levels in the serum of patients with homozygous β-thalassaemia and sickle-cell/ β-thalassaemia.

British Journal of Haematology, 2006; 133 (6): 692-694.

11. Liossis SN, Solomou EE, Sfikakis PP. Lyn deficiency in B cells from patients with systemic lupus erythematosus: comment on the article by FloresBorja et al.

Arthritis and Rheumatism 2006; 54:2036-7 (letter).

12. Sloand EM, Yong ASM, Ramkissoon S, Solomou EE, Bruno TC, Kim S, Fuhrer M, Kajigaya S, Barrett AJ, Young NS. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the soform IV receptor.

Proceedings of the National Academy of Sciences USA 2006; 103: 14483-14488.

13. Sloand EM, Chen G, Pfannes L, Shah S, Solomou EE, Barrett JA, Young NS. CD34 cells from trisomy 8 myelodysplastic syndrome (MDS) patients express early apoptotic markers but avoid programmed cell death by upregulation of anti-apoptotic proteins.

Blood, 2007; 109:2399-405.

14. Solomou EE, Gibellini F, Stewart B, Malide D, Berg M, Visconte V, Green S, Childs R, Chanock SJ, Young NS. Perforin gene mutations in patients with acquired aplastic anemia.

Blood 2007; 109: 5234-5237.

15. Solomou EE, Visconte V, Wong Suzan, Gibellini F, Young NS. Decreased TCR ζ-chain expression in T cells from patients with aplastic anemia.

British Journal of Haematology 2007; 138: 72-76.

16. Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, Barrett AJ, Young NS. FOXP3-positive regulatory T cells in patients with acquired aplastic anemia.

Blood 2007; 110: 1603-1606.

17. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS. [Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.](http://www.ncbi.nlm.nih.gov/pubmed/18250226?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Blood. 2008;111:3675-83 \* Equal second author

18. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP. [Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.](http://www.ncbi.nlm.nih.gov/pubmed/20039407) Arthritis & Rheumatism 2010; 62:150-8

19. Akinosoglou KS, Solomou EE, Gogos CA [Malaria: a haematological disease.](http://www.ncbi.nlm.nih.gov/pubmed/22664049)

Hematology. 2012; 2:106-14.

20. Lagadinou M, Solomou EE, Velissaris D, Theodorou GL, Karakatza M, Gogos CA. [Alterations in T-lymphocyte subpopulations in patients with complicated liver cirrhosis.](https://www.ncbi.nlm.nih.gov/pubmed/23357289) Diagn Microbiol Infect Dis. 2013 Apr;75(4):348-56.

21. Akinosoglou K, Melachrinou M, Siagris D, Koletsis E, Marangos M, Gogos CA, Solomou EE.[Good's syndrome and pure white cell aplasia complicated by cryptococcus infection: A case report and review of the literature.](https://www.ncbi.nlm.nih.gov/pubmed/24627080) J Clin Immunol. 2014 Apr;34(3):283-8

22. Kolyva AS, Zolota V, Mpatsoulis D, Skroubis G, Solomou EE, Habeos IG, Assimakopoulos SF, Goutzourelas N, Kouretas D, Gogos CA. [The role of obesity in the immune response during sepsis.](https://www.ncbi.nlm.nih.gov/pubmed/25244356) Nutr Diabetes. 2014 Sep 22;4:e137. doi: 10.1038/nutd.2014.34.

23. Akinosoglou K, Melachrinou M, Makatsoris T, Sakellakis M, Papakonstantinou C, Gogos CA, Solomou EE [Rituximab as frontline monotherapy in untreated hairy cell leukemia patients.](https://www.ncbi.nlm.nih.gov/pubmed/25672650) Ann Hematol. 2015 Jun;94(6):1069-70.

24. Sotiropoulos C, Theodorou G, Repa C, Marinakis T, Verigou E, Solomou E, Karakantza M, Symeonidis A. [Severe impairment of regulatory T-cells and Th1-lymphocyte polarization in patients with Gaucher disease.](https://www.ncbi.nlm.nih.gov/pubmed/25308560)

JIMD Rep. 2015;18:107-15.

25. Verigou E, Lampropoulou P, Smyrni N, Kolliopoulou G, Sakellaropoulos G, Starakis I, Zikos P, Solomou E, Symeonidis A, Karakantza M.

[Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.](https://www.ncbi.nlm.nih.gov/pubmed/26126819)

Cardiovasc Hematol Disord Drug Targets. 2015;15(2):148-61.

26. Diamantopoulos P, Zervakis K, Zervakis P, Sofotasiou M, Vassilakopoulos T, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Solomou E, Kodandreopoulou E, Papadopoulou V, Korkolopoulou P, Mantzourani M, Kyriakakis G, Viniou NA. [Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.](https://www.ncbi.nlm.nih.gov/pubmed/28212373) Blood Cancer J. 2017 Feb 17;7(2):e533. doi: 10.1038/bcj.2016.127

27. Ntelis K, Solomou EE, Sakkas L, Liossis SN, Daoussis D. [The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.](https://www.ncbi.nlm.nih.gov/pubmed/28602360) Semin Arthritis Rheum. 2017 Dec;47(3):409-417

28. Solomou EE. An update on acquired aplastic anemia. Hematology and Transfusion International Journal. 2017; 4: 57-58

29. Tsanaktsi A, Solomou EE, Liossis SC. Th1/17 cells, a subset of Th17 cells, are expanded in patients with active systemic lupus erythematosus. Clin Immunol. 2018 Oct;195:101-106

30. Diamantopoulos PT, Kontandreopoulou CN, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Vassilakopoulos T, Dimou M, Solomou E, Kyrtsonis MC, Siakantaris M, Angelopoulou M, Kourakli A, Papageorgiou S, Christopoulou G, Roumelioti M, Panayiotidis P, Viniou NA; Hellenic MDS Study Group. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. Ann Hematol. 2019 Jun;98(6):1383-1392.

31. Solomou EE. Idiopathic Aplastic Anemia: An Update. Clinical Hematology International [Volume 1, Issue 1](https://www.atlantis-press.com/journals/chi/issue/295), March 2019, Pages 52 - 57

32. [Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry.](https://www.ncbi.nlm.nih.gov/pubmed/31884152)

Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, Hatzimichael E, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA. Clin Lymphoma Myeloma Leuk. 2019 Sep 28. pii: S2152-2650(19)32001-4. doi: 10.1016/j.clml.2019.09.614

33. [Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen.](https://www.ncbi.nlm.nih.gov/pubmed/31650288)

Solomou EE, Marnellos P, Agathokleous A, Kyriakou G, Georgiou S, Symeonidis A.

Ann Hematol. 2019 Nov;98(11):2625-2626. doi: 10.1007/s00277-019-03818-4.

34. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia. Filippidou M, Avgerinou G, Tsipou H, Tourkantoni N, Katsibardi K, Vlachou A, Roka K, Solomou E, Kattamis A. Br J Haematol. 2020 Jun 12. doi: 10.1111/bjh.16766.

35. [Hepatocellular Carcinoma: An Uncommon Metastasis in the Orbit.](https://pubmed.ncbi.nlm.nih.gov/32158574/)

Protopapa MN, Lagadinou M, Papagiannis T, Gogos CA, Solomou EE. Case Rep Oncol Med. 2020 Feb 26;2020:7526042

36. [Platelets from patients with myocardial infarction can activate T cells.](https://pubmed.ncbi.nlm.nih.gov/32107333/)

Solomou EE, Katsanaki K, Kalyvioti E, Gizas V, Perperis A, Babali D, Verigou E, Gogos H, Hahalis G, Davlouros P, Alexopoulos D.

Haematologica. 2020 Feb 27:haematol.2019.243402

37. [Prognosis of COVID-19: Changes in laboratory parameters.](https://pubmed.ncbi.nlm.nih.gov/32532944/)

Lagadinou M, Solomou EE, Zareifopoulos N, Marangos M, Gogos C, Velissaris D. Infez Med. 2020 Jun 1;28(suppl 1):89-95.

38. [Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced "Eosinophilic Fasciitis-Like" Case and a Review of the Literature.](https://pubmed.ncbi.nlm.nih.gov/33067734/)

Salamaliki C, Solomou EE, Liossis SC. Rheumatol Ther. 2020 Oct 16. doi: 10.1007/s40744-020-00246-z. Online ahead of print

39. How to make the right diagnosis in neutropenia. Solomou EE, Salamaliki C, Lagadinou M. Clinical Hematology International 2021

40. Red Blood Cell Distribution Width: Another prognostic factor for COVID-19? Maria Lagadinou, Despoina Gkentzi, Markos N Marangos, Fotini Paliogianni, Elena E Solomou. Clinical Hematology International 2021

41. Prevalence and significance of mediastinal lymphadenopathy in patients with Severe Acute Respiratory Syndrome Corona Virus-2 infection. F Sampsonas, M Lagadinou, T Karampitsakos, E Solomou, M Doulberis, M Marangos, A Tzouvelekis. European Review for Medical and Pharmacological Sciences 2021; 25:3607

42. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. Panagiotis T Diamantopoulos, Argiris Symeonidis, Vasiliki Pappa, Ioannis Kotsianidis, Athanasios Galanopoulos, Charalampos Pontikoglou, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megalakaki, Panagiotis Repousis, Maria Kotsopoulou, Maria Dimou, Elena Solomou, Georgios Dryllis, Dimitrios Tsokanas, Menelaos‐Konstantinos Papoutselis, Sotirios Papageorgiou, Marie‐Christine Kyrtshonis, Alexandra Kourakli, Helen Papadaki, Panayiotis Panayiotidis, Nora‐Athina Viniou. British J Haematol 2021; 192:978

43. "[Alterations in Lymphocyte subsets and Monocytes in patients diagnosed with SARS-CoV-2 pneumonia: a mini review of the literature.](https://www.publishingmanager.org/author/your_articles/alterations_in_lymphocyte_subsets_and_monocytes_in_patients_diagnosed_with_sars_cov___pneumonia__a_mini_review_of_the_literature__24086)" Maria Lagadinou, Nicholas Zareifopoulos, Despoina Gkentzi, Fotios Sampsonas, Eirini Kostopoulou, Markos Marangos ,Elena Solomou,

European Review for Medical and Pharmacological Sciences. 2021.

44. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine

Kontandreopoulou CN, Diamantopoulos PT, Giannopoulos A, Symeonidis A, Kotsianidis I, Pappa V, Galanopoulos A, Panayiotidis P, Dimou M, Solomou E, Loupis T, Zoi K, Giannakopoulou N, Dryllis G, Hatzidavid S, Viniou NA; Hellenic MDS study Group.

Leuk Lymphoma. 2021 Nov 5:1-9. doi: 10.1080/10428194.2021.1998484.

45. Ilias Christodoulou, Win Jin Ho, Andrew Marple, Jonas W Ravich, Ada Tam, Ruyan Rahnama, Adam Fearnow, Cambrynne Rietberg, Sean Yanik, Elena E Solomou, Ravi Varadhan, Michael A Koldobskiy, Challice L Bonifant Engineering CAR-NK cells to secrete IL15 sustains their anti-AML functionality, but is associated with systemic toxicities. J Immunotherapy Cancer 2021. In press

46. Lagadinou M, Gogos C, Karatzogiannis G, Solomou EE. [Alterations in neutrophil to lymphocyte ratio: An inexpen-sive, reproducible prognostic marker in patients with complicated liver cirrhosis](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=vKxwthMAAAAJ&sortby=pubdate&citation_for_view=vKxwthMAAAAJ:HoB7MX3m0LUC). J Clin Images Med Case Rep 2022; 3: 1637

47. Solomou EE. Copper deficiency. EJHaem. 2022; 3: 539-40.

48. Diamantopoulos PT, Kontandreopoulou CN, Gkoufa A, Solomou E, Anastasopoulou A, Palli E, Kouzis P, Bouros S, Samarkos M, Magiorkinis G, Gogas H. Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in patients with melanoma treated with immunotherapy. Cancers 2022;14:3791

49. Delaporta P, Terpos E, Solomou E, ….Kattamis A. Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia. Br J Haematol 2022

50. [Immunogenicity and safety of the BNT162b2 mRNA Covid-19 vaccine in patients with melanoma treated with immunotherapy](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=vKxwthMAAAAJ&sortby=pubdate&citation_for_view=vKxwthMAAAAJ:3s1wT3WcHBgC)

PT Diamantopoulos, CN Kontandreopoulou, A Gkoufa,E Solomou, …H Gogas.

Cancers 2022; 14: 3791

51. [Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=vKxwthMAAAAJ&sortby=pubdate&citation_for_view=vKxwthMAAAAJ:dfsIfKJdRG4C)

PT Diamantopoulos, E Charakopoulos, A Symeonidis, I Kotsianidis, …Solomou E, ….

Scientific Reports 2022; 12:, 17914

52. The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms. Diamantopoulos P, Solomou E, Symeonidis A, Pappa V…., Nora-Athina Viniou.  Am J Hematol 2023

53. [Ischemic stroke in a pediatric patient with very rare coexistence of sickle-cell/β-thalassemia and neurofibromatosis type 1](https://pubmed.ncbi.nlm.nih.gov/37057739/)

Kleoniki Roka, Elena Solomou, Stavros Glentis, Maria Gavra, Eleftheria Kokkinou, Efthymia Rigatou, Roser Pons, Antonis Kattamis

Pediatric blood & cancer, 2023, e30364

54. Telomere biology: from disorders to hematological diseases. Roka K, Solomou EE, Kattamis A. Frontiers in Oncology, 2023, In press

55. [Evidence That Platelets from Transfusion-Dependent Thalassemia Patients Induce T Cell Activation](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=vKxwthMAAAAJ&sortby=pubdate&citation_for_view=vKxwthMAAAAJ:pyW8ca7W8N0C). Solomou EE, Polyxeni Delaporta, Aimilia Mantzou, Marianna Tzannoudaki, Panagiotis T Diamantopoulos, Christina Salamaliki, Christina-Nefeli Kontandreopoulou, Athina Vyniou, Foteini Perganti, Ioannis Papassotiriou, Antonis Kattamis. Clinical Immunology, 2023 In press

56. A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia. Christodoulou I, Solomou EE. Cancers 2023, In press

57. Diamantopoulos P, Avagyan S, **Solomou EE.** Biological Aspects of Bone Marrow Failure.

Frontiers in Oncology 2023; 13: 1295823

58. Chatzikalil E, Kattamis A, Diamantopoulos P, SolomouEE. Post SARS-CoV-2 vaccination newly diagnosed Aplastic Anemia. International Journal of Hematology. Accepted for publication

59. **Solomou ΕΕ**, Kattamis Α, Symeonidis Α, Sirinian C, Salamaliki, C, Tzanoudaki M, Diamantopoulos P, Plakoula E, Palasopoulou M, Giannakoulas N, Kontandreopoulou CN, Kollia P, Viniou NA, A Galanopoulos, Liossis SN, Vassilopoulos G.

Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ. Blood Advances 2024:8;2:399-402

60. Chatzikalil E, Roka N, Diamantopoulos P, Rigatou E, Avgerinou A, Kattamis A, **Solomou EE.** Venetoclax combination treatment of Acute Myelogenous Leukemia in adolescents and young adult patients.  J Clin Medicine , 2024 epub ahead of print

61. Pouliasi F, Salamaliki C, Kanaloupitis S, Verigou E, Liolis E, Koutras A, Makatsoris T, Kalofonos C, Liossis SN, **Solomou EE**

 [Exploring the Dynamics of B Cell Subpopulations in Response to Immune Checkpoint Inhibitors: A Prospective Study](https://www.mdpi.com/2076-3417/14/12/4990). Applied Sciences 2024;14:4990

62. Salamaliki C, Pouliasi F, Liolis E, Verigou E, Koutras A, Makatsoris T, Kalofonos C, Liossis SN, **Solomou EE** (2024) Evidence That Circulating T Cells at Treatment Onset Predict Response to PD-1 Inhibitors. Ann Case Report. 9: 1788. <https://doi.org/10.29011/2574-7754.101788>

**Selected Research Grants:**

2005 – 2006: “Interferon-γ overproduction in patients with aplastic anemia and myelodysplastic syndromes at the molecular level: the role of transcription factors”.

Aplastic Anemia and Myelodysplastic Syndrome International Foundation, USD 10.000. Principal Investigator.

2004 – 2006: “The effects of alpha interferon on the production of interleukin 2 from T cells of patients with Systemic Lupus Erythematosus”

Hellenic Rheumatology Society, €5.000. Co-investigator.

2011 – 2013: “The pathogenic role of novel T cell subsets in patients with myelodysplastic syndromes and aplastic anemia: A study of the phenotype and the molecular mechanisms controlling the expression and function of Th17, TFH and Treg T cells”.

\*The University of Patras “Karatheodoris” program of Basic Research Grants, € 30.000.

* The “Karatheodoris” Grants of the University of Patras represent the most prestigious, highly - competitive grants offered by this institution. Funding stems directly from the Greek Government (Public Investments Program).

“Askleipios” Research grant from Gilead for the project entitled: “T regs and HIV”. (€5.000 Principal Investigator)

Research grant from the Greek Society of Cardiology for the research project “Platelets can activate T cells in patients with MI” ( €10.000 Principal Investigator) (2019)

Research grant from the Greek Society of Hematology ( €10.000 Principal Investigator) for the research project” T and B cell crosstalk in patients with aplastic anemia”(2020)

Research grant from P&G ( €20.000 Principal Investigator) for the research project “ T cells in patients with neutropenia” (2022).

| MEMBERSΗIPS  |
| --- |
| 2022-today | Member of the scientific committee-advisory board for the annual Conference of the European Hematology Association 2023National representative at the “Lighting the flame “ initiative, EHACoordinating reviewer for bone marrow failure-research at the EHA2023 abstracts  |
| 2021 | Reviewer in the committee for the Bone Marrow Failure section at the Annual Meeting of the American Society of Hematology  |
| 2017-today | International Academy of Clinical Hematology (IACH) (Founding Member) |
| 2009-today | Cyprus Hematology Association (Founding Member) |
| -today  | EHA member |
| 2006-today | Fellow of the American Society of Hematology. |
| 2002 - present | Hellenic Hematology Association (Full Member). |

**Scholarships and Awards**

1. 1st Award at the Pan-Hellenic Medical Congress (Athens). 1st Award in Basic Medical Research “Identification and characterization of E4.5 gene located at 13q14 chromosomal locus. A guanine nucleotide exchange factor that is defective in patients with Chronic Lymphocytic Leukemia” (2000).

2. The Henry Christian Award (American Federation of Medical Research) for “Excellence in Medical Research”. (March 2001)

3. The Hans Wyder Scholarship from the European School of Oncology. (February 2004)

4. The “Papagiannis Memorial Scholarship” from the Hellenic Hematology Society for my research project entitled “Mechanisms of interferon-γ overproduction in patients with aplastic anemia and myelodysplastic syndromes at the molecular level”. (June 2006)

5. The “Argagathos Goutas” award from the Hellenic Hematology Association for the research project entitled : “Platelets act as antigen presenting cells in patients with myocardial infarction” (2016)

6. The “Lichterzellen scholarship award” from the European School of Hematology (EHA-EBMT Translational Research Conference: Bone Marrow Failure Syndromes")

6. The “F.Fessas” award from the Hellenic Hematology Association for the research project entitled: “T and B cell crosstalk in patients with aplastic anemia, the role of transcription factor Ets-1” (2022).

**Supervision of Graduate students**

1. 2018-2021: Katerina Katsanaki: Platelets act as antigen presenting cells in patients with myocardial infarction (PhD, completed)
2. 2019-2023: Salamaliki Christina: The effect of PD-1inhibitors on T cells (PhD, completed,)
3. 2021-today: Elias Christodoulou: Engineering CAR-NK cells in AML (PhD, completed,)
4. 2019-2023: Pouliasi Foteini: The effect of PD-1inhibitors on B cells (PhD, completed, awaiting for thesis defence)

**Teaching activities**

1. ΝΙΗ, Hematology Branch: Team leader (5 postgraduate students ) studying the immunological basis of bone marrow failure syndromes .

2. Teaching of postgraduate students at the Rheumatology Research Lab and the Hematology Research Lab of the Dept of Internal Medicine, University of Patras Medical School. (March 2008 – Today)

3. Teaching the lesson “Aplastic Anemia and PNH”, and MDS at the “Hellenic Hematology Association Education Program” for the fellows in Hematology nationwide.

4 Teaching at the “Postgraduate training program in Hematology” for the Hematology Fellows of the Dept of Medicine, Patras University Hospital and Ioannina University Hospital.

5. Courses in “Pathology”: 3rd yr Medical Students, University of Patras Medical School.

6. Teaching at the “Postgraduate training program in Medicine” for the Internal Medicine Fellows of Patras University Hospital.

7. Teaching (small group teaching in the class and at bedside) in “Clinical Skills” for 1st ,2nd and 3rd yr Medical Students, University of Patras Medical School.

8. Person-in-Charge for the clinical training and examination of 5th and 6th yr Medical Students rotating in Internal Medicine, University of Patras Medical School.

9. Teaching the Hematology course for the third year medical students, University of Patras Medical School

10. Teaching Physiology and Hematology at the European University Cyprus (Visiting Professor 2014-2017)

11. Teaching at the Postgraduate program at the University of Athens Medical School “infectious Diseases”(2020-today)

12. Teaching at the Postgraduate program at the University of Athens Medical School “Hemostasis and Transfusion Medicine”(2020-today)

13. Teaching at the Postgraduate program at the University of Crete Medical School “Hematology-Oncology in Children and adolescents”(2020-today)

14. Teaching undergraduate students at the University of Athens Medical School (Visiting Professor 2021-today).

**Book Chapters**

1. Major Contributor «Molecular Basis and Pathophysiology of Blood Disorders» N.C. Zoumbos, Editor, Pikramenos Publishing Group, Patras, Greece, 2009.

2. Solomou EE. The Role of Transplantation in Acquired Aplastic Anemia. *In*: New Insights in Hematopoietic Cell Transplantation, A.Spyridonides, I Sakellari, Editors. Research Signpost, 2010.

3. Aplastic Anemia. Notes in Internal Medicine, University of Thessaloniki Medical School 2017

4. Aplastic Anemia and Inherited Bone marrow failure syndromes. Hematology (2022, Editors: M. Aggelopoulou, G. Pangalis)

**Invited speaker**

Over the past ten years invited to give more than 100 invited lectures in different conferences and seminars in Greece and abroad (selected below)

1. The pathophysiology of Aplastic Anemia, Verona, Italy, 2023
2. Aplastic Anemia: An update Alexandroupolis 2023
3. What’s new in the treatment of Aplastic Anemia, Larissa 2023
4. Aplastic anemia, pathophysiology and treatment Paris 2022
5. Aplastic Anemia, USA 2022
6. Neutropenia-How to make the right diagnosis , Paris 2019

3. The role of Mutations in Aplastic Anemia , Thessaloniki November 2018

4. Hairy Cell Leukemia; an update , Paris September 2018

5. Update on Aplastic Anemia, Porto Heli September 2018

6. “Treatment of Aplastic Anemia”, Athens May 2018, Hellenic Society of Hematology

7. “Interpretation of CBC”, Patras March 2018

8. “New Concepts in Aplastic Anemia”, February 2018, Larissa

9. “Monoclonal antibodies and infections” Patras 2017

10. “ Pathophysiology and Treatment of Aplastic Anemia” Athens, November 2017

11. “ Novel treatment options in Aplastic Anemia” Rhodes, September 2017

12. “Neutropenia and Trisomy 8”. Kavala, EAE, October 2017

13. “Pathophysiology and treatment of Aplastic Anemia” Alexandroupoli, May 2017

14. “Pathophysiology of TTP” Larissa, February 2017

15. “What’s new in Aplastic Anemia” Larissa, February 2017

16. “Hypoplastic Myelodysplastic Syndromes” Thessaloniki, EAE, November 2016

17. “Aplastic Anemia”, Ioannina November 2016

18. “Aplastic Anemia; novel data on pathophysiology and treatment” Larissa, February 2016

**Reviewing activity**

1.Blood

 2.The Journal of Immunology

3. Clinical Immunology

4. Lupus

5. Immunological Investigations

6. PLoS One

7. Turkish Journal of Hematology

8. Advances in Hematology

9. British Journal of Haematology

10. Biology of Bone Marrow Transplantation

11. Clinical Hematology International

12. Frontiers in Immunology (Section Editor)

13.Clinical and Translational Science

14. Frontiers in Oncology (Guest Editor )

**Other:**

1. Person-in charge for the National guidelines on the diagnosis and treatment of Aplastic anaemia (2018)-updated 2022.
2. Member of the International IPIG committee for the PNH guidelines (2023-today)
3. Member of the scientific committee and advisory board member of the annual scientific conference EHA (2022-today)
4. Reviewer for the bone marrow failure abstracts for the ASH 2021
5. Chair of the committee for the bone marrow failure abstracts EHA2023, 2024